STOCK TITAN

Assembly Bioscie - ASMB STOCK NEWS

Welcome to our dedicated page for Assembly Bioscie news (Ticker: ASMB), a resource for investors and traders seeking the latest updates and insights on Assembly Bioscie stock.

Company Overview

Assembly Biosciences, Inc. (ASMB) is a clinical-stage biotechnology company dedicated to the discovery and development of novel oral therapeutics designed to address serious viral diseases. With a dual-platform strategy focused on innovative approaches, the company is advancing a new class of oral antiviral therapeutics for hepatitis B virus (HBV) infection as well as pioneering oral live biotherapeutics aimed at restoring the health of dysbiotic microbiomes.

Innovative Therapeutic Platforms

The company’s strategic development is built on two core programs:

  • HBV Therapeutics: Assembly Biosciences is developing investigational small-molecule compounds that target critical phases of the HBV lifecycle. These candidates aim to overcome the limitations of current chronic HBV treatments by targeting multiple steps in viral replication and reducing the viral reservoir, which has historically resulted in low cure rates.
  • Microbiome Therapeutics: Leveraging a fully integrated platform, Assembly Biosciences has created a proprietary approach for identifying, isolating, and cultivating beneficial microbial strains. This platform, complemented by a patent-pending delivery technology, is designed to formulate oral live biotherapeutics that may address disorders associated with microbiome dysregulation.

Clinical Development and Research Focus

Assembly Biosciences operates at the forefront of antiviral drug development. Its clinical-stage programs are rigorously designed to assess safety, tolerability, and pharmacokinetics across multiple investigational candidates. The company’s robust pipeline is anchored by its commitment to advancing therapies that target the underlying mechanisms of viral infections, with research spanning from preclinical studies to early-stage clinical trials. The emphasis on oral delivery systems not only supports ease of administration but also reflects modern trends in patient-centric care.

Scientific Rationale & Differentiation

The research and development efforts are underscored by thorough mechanistic studies and innovative drug design strategies. By directly targeting key viral proteins and pathways, Assembly Biosciences aims to disrupt viral replication effectively. The incorporation of state-of-the-art strain selection methods in its microbiome program further highlights the company’s technical expertise. This combination of antiviral and microbiome-focused strategies provides a unique platform differentiating Assembly Biosciences from other entities in the competitive biotechnology landscape.

Market Position & Value Proposition

Positioned in a challenging segment of the biotechnology industry, Assembly Biosciences addresses significant unmet medical needs in the treatment of chronic viral infections. The company’s approach leverages long-standing expertise in virologic drug development and integrates rigorous clinical protocols with innovative oral delivery mechanisms. This has facilitated progress across multiple investigational therapies, which are being evaluated through well-designed clinical studies. The strategic emphasis on high-impact diseases such as HBV and conditions linked to microbiome imbalances establishes a clear value proposition to the public health sector.

Research Infrastructure and Strategic Collaborations

Assembly Biosciences benefits from an accomplished leadership team with extensive expertise in antiviral therapeutics and clinical research. Strategic collaborations with renowned partners further strengthen its research and development capabilities. This collaborative approach not only enhances the technical and clinical knowledge base but also provides a robust framework for addressing the safety and efficacy challenges associated with novel drug candidates.

Commitment to Innovation and Scientific Excellence

Underpinned by a deep commitment to scientific rigor and innovation, Assembly Biosciences continuously refines its therapeutic strategies by integrating advanced pharmacokinetic modeling, comprehensive preclinical assessments, and early-stage clinical data. The company’s methodical approach ensures that all therapeutic candidates are evaluated meticulously, thereby promoting a balanced view of potential benefits while maintaining high standards of safety and research integrity. This dedication forms the basis for sustained research excellence and positions Assembly Biosciences as a trusted informational resource in the biotechnology sector.

Rhea-AI Summary

Assembly Biosciences has initiated a Phase 1a/b clinical trial for ABI-5366, a new helicase-primase inhibitor targeting herpes simplex virus (HSV). The Phase 1a trial involves single ascending doses in healthy participants, with interim data expected by Q3 2024. Phase 1b will start by the end of the year with multiple ascending weekly doses in patients with recurrent genital herpes, with interim data expected in the first half of 2025. ABI-5366 has shown strong potential in preclinical studies, potentially offering a long-acting treatment for HSV-1 and HSV-2. Existing treatments are and not fully effective, highlighting the need for new therapeutic options in this area.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.51%
Tags
-
Rhea-AI Summary

Assembly Biosciences showcased new preclinical data for ABI-6250, an orally bioavailable hepatitis D virus (HDV) entry inhibitor, at the EASL Congress 2024. The data underline ABI-6250's potential to block HDV from entering cells, targeting the NTCP bile acid transporter with high selectivity. The preclinical results showed effective inhibition of HDV infection and NTCP-mediated bile acid uptake, supporting once-daily oral dosing. Clinical trials are expected to begin by the end of 2024. Chronic HDV is a severe viral hepatitis form, leading to liver complications and potential death. ABI-6250 promises to be a significant therapeutic innovation in viral hepatitis treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
none
-
Rhea-AI Summary

Assembly Biosciences (Nasdaq: ASMB) will present preclinical data from its HSV and HDV therapeutics at the International Herpesvirus Workshop (July 13-17, 2024) and EASL Congress 2024 (June 5-8, 2024). Data for ABI-5366 and ABI-1179, targeting recurrent genital herpes, will be featured in one oral and two poster presentations. ABI-6250, aimed at treating chronic hepatitis D, will be presented as a poster. The company anticipates starting clinical trials for ABI-5366 mid-year and for ABI-1179 and ABI-6250 by the end of 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
conferences
Rhea-AI Summary

Assembly Biosciences, Inc. (Nasdaq: ASMB) reported financial results for Q1 2024, including regulatory clearances for Phase 1 trials for ABI-5366 targeting recurrent genital herpes and ABI-4334 in chronic HBV infection. The company highlighted upcoming clinical milestones, abstract acceptance for ABI-6250 at EASL CongressTM 2024, and financial results showing $113.0 million in cash as of March 31, 2024. Revenues from collaborative research were $5.8 million, with research and development expenses at $11.9 million and a net loss of $9.1 million for Q1 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
-
Rhea-AI Summary
Assembly Biosciences, Inc. reported financial results for Q4 2023 and year-end 2023, showcasing progress in antiviral pipeline development. The company entered a partnership with Gilead Sciences, strengthened leadership, and filed a clinical trial application for ABI-5366. Anticipated milestones include interim data from Phase 1a studies by Q3 2024 and Phase 1b studies by end of 2024. Financially, the company's cash position improved significantly, with $130.2 million in cash, cash equivalents, and marketable securities as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
-
Rhea-AI Summary
Assembly Biosciences, Inc. (ASMB) announced a 1-for-12 reverse stock split of its outstanding shares, reducing the number of shares from approximately 65.8 million to approximately 5.5 million. The split will not affect the number of authorized shares or the par value of the common stock. The split is expected to bring the company into compliance with the minimum bid price requirement for maintaining its listing on The Nasdaq Global Select Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
Rhea-AI Summary
Assembly Biosciences, a biotechnology company (Nasdaq: ASMB), plans to expand its R&D portfolio across herpesviruses and hepatitis B and D viruses. They anticipate four development candidates to be in the clinic by the end of 2024, with initial clinical data expected by the end of the year from the first-in-human study of long-acting helicase-primase inhibitor targeting recurrent genital herpes (ABI-5366) and Phase 1b study of next-generation core inhibitor for chronic hepatitis B virus (ABI-4334). Assembly Bio recently announced a long-term partnership with Gilead Sciences, Inc. to address serious viral diseases, expanding and building on the progress of their antiviral portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Assembly Biosciences, Inc. (ASMB) Announces Grant of Inducement Awards to Chief Medical Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
none
-
Rhea-AI Summary
Assembly Biosciences, Inc. (Nasdaq: ASMB) announced new data from its virology portfolio at the American Association for the Study of Liver Diseases (AASLD), highlighting the potential of its preclinical IFNAR agonist program to improve tolerability and the results of vebicorvir in combination with Nrtl and AB-729 in virologically suppressed patients with hepatitis B e antigen negative chronic HBV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Assembly Biosciences, Inc. (ASMB) has partnered with Gilead Sciences to develop treatments for herpesviruses, HBV, and HDV, with 4 candidates expected in clinical development by the end of 2024. The $100 million upfront payment and investment from Gilead extends cash runway into 2H 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags

FAQ

What is the current stock price of Assembly Bioscie (ASMB)?

The current stock price of Assembly Bioscie (ASMB) is $11.12 as of March 7, 2025.

What is the market cap of Assembly Bioscie (ASMB)?

The market cap of Assembly Bioscie (ASMB) is approximately 72.7M.

What is the core focus of Assembly Biosciences?

Assembly Biosciences is a clinical-stage biotechnology company that develops innovative oral therapeutics for the treatment of chronic viral infections and disorders associated with microbiome dysregulation.

How does Assembly Biosciences generate revenue?

The company primarily pursues revenue through advancing its clinical-stage pipeline and establishing strategic collaborations, which may include licensing agreements and partnerships with industry leaders in antiviral and microbiome therapeutic research.

What therapeutic areas does the company target?

Assembly Biosciences focuses on addressing serious viral diseases such as hepatitis B and conditions related to microbiome imbalances through its dual-platform approach in antiviral and biotherapeutic research.

How do their HBV investigational therapies work?

Their HBV program is designed to disrupt multiple steps of the HBV lifecycle by using small-molecule agents that interfere with viral replication processes, potentially increasing cure rates compared to current treatments.

What sets their microbiome therapeutics apart?

The microbiome platform leverages an integrated technology that includes robust strain identification, precision isolation, and a patent-pending delivery system, ensuring targeted administration and improved therapeutic outcomes.

How is Assembly Biosciences positioned in the competitive landscape?

By combining rigorous clinical research with innovative oral delivery strategies, the company differentiates itself in a competitive market, addressing significant unmet needs in treatment of chronic viral infections and microbiome-associated disorders.

What role do strategic collaborations play in the company’s development efforts?

Collaborations with established industry partners bolster Assembly Biosciences' research capabilities, enhance its clinical development programs, and provide access to additional resources and expertise in antiviral drug development.

What are the key advantages of their oral therapeutic platforms?

Oral administration offers improved patient compliance and ease of use compared to traditional therapies, while the innovative designs of these platforms are supported by advanced pharmacokinetic studies and early clinical data demonstrating favorable safety profiles.
Assembly Bioscie

Nasdaq:ASMB

ASMB Rankings

ASMB Stock Data

72.65M
5.58M
31.62%
18.79%
0.26%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO